Inhaled Insulin Provides Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral AgentsA Randomized Controlled Trial

Open Access
Publisher Website
Google Scholar
Abstract
TYPE 2 diabetes mellitus represents a heterogeneous metabolic dysfunction, with patients displaying defects in insulin secretion and peripheral insulin sensitivity. Functional defects in the pancreatic beta cell are crucial to the development of type 2 diabetes mellitus1-4 and occur early in the course of the disease.5,6 Oral antihyperglycemic agents (OHAs) depend on pancreatic beta cell function for their action; therefore, their maximal efficacy is limited by dose-response considerations and by declining beta cell function. A high proportion of patients with type 2 diabetes mellitus has poor glycemic control, despite therapeutic dosages of OHAs.7